Clinical Trial Update: The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease [Phase 3]

View source ↗

Summary

Phase 3 trial results from the RENEW study evaluating Reproxalap for dry eye disease have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease

Drugs mentioned

• Reproxalap (reproxalap)

Snippet

Sponsor: Aldeyra Therapeutics, Inc. | Conditions: Dry Eye | Phase 3 | Status: COMPLETED | Results posted: 2025-01-23